000			03419nam a2200433 c4500
003			ES-MaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnanaaa
710	2		_aSpringerLink (Online service) _9106996
999			_c115149 _d115149 _x1
001			115149
005			20230102113652.0
008			190702s2019 gw a o |||| 0|eng d
020			_a9783030190194
024	7		_a10.1007/978-3-030-19019-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.B6 _b2019 EB
245	0	0	_aMolecular Imaging in Multiple Myeloma _cedited by Cristina Nanni, Stefano Fanti, Lucia Zanoni.
250			_a1st ed. 2019.
264		1	_aCham _bSpringer International Publishing _c2019.
300			_a1 recurso en línea (V, 136 páginas) _b 57 ilustraciones, 38 ilustraciones a color.
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aMedicine (Springer-11650)
505	0		_a1.Multiple Myeloma: clinical aspects -- 2. What does a clinician need from new imaging procedures? -- 3.FDG PET in Multiple Myeloma -- 4. Role of Standard Magnetic Resonance Imaging -- 5.Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A new era for whole body imaging in myeloma? -- 6.CXCR4 imaging in Multiple Myeloma -- 7.PET/CT with Standard NON-FDG Tracers -- 8. The issue of interpretation -- 9. Clinical Teachning Cases: FDG PET/CT .
520	3		_aThis book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/or evaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.
988			_aSpringer_Medicine_2019
650		7	_2embne _9182468 _aHuesos _xTumores
700	1		_aNanni, Cristina _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _988786
700	1		_aFanti, Stefano _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _988787
700	1		_aZanoni, Lucia _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt _988788
776	0	8	_iPrinted edition: _z9783030190187
776	0	8	_iPrinted edition: _z9783030190200
776	0	8	_iPrinted edition: _z9783030190217
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-19019-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b11/2019 _ea _zSI